Stocks · News reference
Filed: 2026-11-09 AccNo: 0001213900-26-117552 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Rafael Holdings, Inc. announced it will participate in a fireside chat and host one-on-one meetings with institutional investors at the Guggenheim 3rd Annual Healthcare Innovation Conference.
Rafael Holdings, Inc. announced its financial results for the fourth quarter and full fiscal year ended July 31, 2026, reporting a narrowed net loss compared to the prior year.
Rafael Holdings, Inc. announced that its subsidiary, Cyclo Therapeutics, LLC, has submitted a New Drug Application (NDA) to the FDA for remibetadex to treat Niemann-Pick Disease Type C.
U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and Q2 GDP was revised higher.
Rafael Holdings (NYSE: RFL) stock tumbles after its Phase 3 TransportNPC study of Trappsol Cyclo misses its primary endpoint.